MEDFORD, N.Y., Nov. 09, 2018 (GLOBE NEWSWIRE) — Chembio Diagnostics, Inc. (Nasdaq: CEMI), a leader in point-of-care diagnostic tests for infectious diseases, today announced plans to participate in two upcoming investor conferences.
Chembio’s Chief Executive Officer, John Sperzel, will be participating in one-on-one meetings at the Craig-Hallum Alpha Select Conference on Thursday, November 15, 2018.
Chembio’s Chief Financial Officer, Neil Goldman, is scheduled to present at the Canaccord Genuity Medical Technologies & Diagnostics Forum on Thursday, November 15, 2018, at 11:30 am Eastern Time. Interested parties may access a live or recorded webcast of the presentation on the “Investor Relations” section of the company’s website at www.chembio.com. Mr. Goldman will also be participating in one-on-one meetings at the conference.
About Chembio Diagnostics
Chembio is a leading point-of-care diagnostics company focused on detecting and diagnosing infectious diseases. The company’s patented DPP® technology platform, which uses a small drop of blood from the fingertip, provides high-quality, cost-effective results in 15 to 20 minutes. Coupled with Chembio’s extensive scientific expertise, its novel DPP® technology offers broad market applications beyond infectious disease, a number of which are under active development with collaboration partners. Chembio’s products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers. Learn more at www.chembio.com.
Media contact:
| Lynn Pieper Lewis Gilmartin Group (415) 937-5402 investor@chembio.com |